ClinConnect ClinConnect Logo
Search / Trial NCT03821779

Prefrontal Oscillations in Social Anxiety Disorder (POSAD)

Launched by INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, FRANCE · Jan 25, 2019

Trial Information

Current as of July 26, 2025

Recruiting

Keywords

ClinConnect Summary

The clinical trial titled "Prefrontal Oscillations in Social Anxiety Disorder" (POSAD) is investigating a specific brain activity pattern in people with social anxiety disorder. Researchers believe that slow electrical waves in a part of the brain called the prefrontal cortex might help identify those with severe anxiety. By studying these brain patterns in humans, the trial aims to better understand how anxiety works and potentially improve treatment options in the future.

To participate in this study, individuals must have been diagnosed with social anxiety disorder and be registered with the French national health insurance system. Participants should also be able to understand the study details and provide their consent to join. However, certain health conditions or recent changes in medication may disqualify someone from participating. If selected, participants can expect to undergo tests that will measure their brain activity while researchers gather information to better understand anxiety. It's an exciting opportunity to contribute to important research in mental health!

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Social anxiety disorder as defined in DSM-5
  • Full understanding of the protocol
  • Obtaining informed consent from study subjects before or at inclusion at the latest
  • Being registered in the french national health insurance service (Sécurité Sociale) (or equivalent)
  • Exclusion Criteria:
  • Active medical co-morbidity including severe hypertension, cardiac insufficiency, Raynaud syndrome, diabetes mellitus, renal insufficiency, adrenal insufficiency, Cushing syndrome and epilepsy
  • Severe neurological co-morbidity, including but not limited to Parkinson's disease and multiple sclerosis
  • Long-term corticotherapy
  • History of significant head injury, defined by loss of consciousness
  • Being diagnosed with another major psychiatric condition (DSM5) including bipolar disorder and schizophrenia or substance/alcohol use disorder; with the exception of major depressive disorder and nicotine use disorder
  • Suicidal risk evaluated as moderate to high in the MINI questionnaire
  • * initiation of a psychotropic treatment or change in the dose of ongoing psychotropic treatment within 3 days prior to each visit and including:
  • 1. antidepressant treatments with selective serotonin recapture inhibitors, serotonin and norepinephrine inhibitors, alpha2-presynaptic adrenoreceptors (mirtazapine, mianserin), tricyclic
  • 2. anxiolytic drugs including benzodiazepines and anti-histamine
  • 3. antipsychotic drugs
  • Acute alcohol intake 2 days prior to each visit (inclusion, experimental sessions)
  • Pregnancy or breastfeeding.
  • Ongoing hospitalization without consent (decision of a third-party: medical, justice)

About Institut National De La Santé Et De La Recherche Médicale, France

The Institut National de la Santé et de la Recherche Médicale (INSERM) is France's key public research organization dedicated to advancing knowledge in health and biomedical sciences. Established to foster innovation and improve public health outcomes, INSERM conducts a wide range of clinical trials and research initiatives aimed at translating scientific discoveries into effective medical treatments and interventions. With a focus on collaboration among researchers, healthcare professionals, and industry partners, INSERM plays a pivotal role in shaping health policies and enhancing the quality of care in France and beyond.

Locations

Bordeaux, , France

Patients applied

0 patients applied

Trial Officials

Olivier Doumy, MD

Principal Investigator

Centre Hospitalier Charles Perrens, Bordeaux; INRA NutriNeuro, Bordeaux; Université de Bordeaux, France

Alexandra Bouvard, MD

Principal Investigator

Centre Hospitalier Charles Perrens, Bordeaux; Université de Bordeaux, France

Cyril Herry, PhD

Study Director

Neurocentre Magendie, Inserm U1215, Bordeaux, France

Cyril Dejean, PhD

Principal Investigator

Neurocentre Magendie, Inserm U1215, Bordeaux, France

Thomas Bienvenu, PhD

Principal Investigator

Centre Hospitalier Charles Perrens, Bordeaux; Neurocentre Magendie, Inserm U1215, Bordeaux, France

Jacques Taillard, MS

Principal Investigator

GENPHASS, CHU de Bordeaux

Bruno Aouizerate, MD-PhD

Study Chair

Centre Hospitalier Charles Perrens, Bordeaux; INRA NutriNeuro, Bordeaux; Université de Bordeaux, France

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials